Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Details for Australian Patent Application No. 2004217434 (hide)

Owner Alexion Pharmaceuticals, Inc.

Inventors McWhirter, John; Kretz-Rommel, Anke; Bowdish, Katherine S.

Agent Freehills

Pub. Number AU-B-2004217434

PCT Pub. Number WO2004/078938

Priority 10/379,151 04.03.03 US; 10/736,188 15.12.03 US

Parent 2002246632

Filing date 4 March 2004

Wipo publication date 16 September 2004

Acceptance publication date 26 August 2010

International Classifications

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/07 (2010.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Animal cells or tissues

C12N 5/071 (2010.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Vertebrate cells or tissues, e.g. human cells or tissues

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

G01N 33/567 (2006.01) Investigating or analysing materials by specific methods not covered by groups - utilising isolate of tissue or organ as binding agent

G01N 33/569 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for micro-organisms, e.g. protozoa, bacteria, viruses

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

22 September 2005 PCT application entered the National Phase

  PCT publication WO2004/078938 Priority application(s): WO2004/078938

11 March 2010 Amendment Made

  The nature of the amendment is: Add priority details under INID (62) 2002246632

26 August 2010 Application Accepted

  Published as AU-B-2004217434

23 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004217437-Use of antisense oligonucleotides or siRNA to suppress expression of eIF5A1

2004217433-Vectors used to create hybrid constant regions